16,914 Shares in Bristol Myers Squibb Company $BMY Acquired by Van Hulzen Asset Management LLC

Van Hulzen Asset Management LLC acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 16,914 shares of the biopharmaceutical company’s stock, valued at approximately $975,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Life Cycle Investment Partners Ltd acquired a new position in Bristol Myers Squibb in the fourth quarter valued at about $34,406,000. Lazard Asset Management LLC grew its position in shares of Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after buying an additional 368,193 shares during the period. Axxcess Wealth Management LLC increased its stake in shares of Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after acquiring an additional 21,196 shares during the last quarter. BlackRock Inc. increased its stake in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. Finally, Asset One Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $4,075,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Up 0.4%

BMY stock opened at $67.30 on Tuesday. The company has a market cap of $137.47 billion, a price-to-earnings ratio of 14.82, a P/E/G ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The business has a 50 day moving average price of $60.77 and a two-hundred day moving average price of $59.47. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter in the prior year, the business posted $1.46 EPS. The business’s revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. Bristol Myers Squibb’s payout ratio is currently 55.51%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on BMY shares. Piper Sandler started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued an “overweight” rating on the stock. Guggenheim reissued a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a research report on Friday, July 31st. Raymond James Financial began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Finally, Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.